Genomic Health's Oncotype DX® Becomes First Multi-Gene Test for Cancer Management To Be Included in National Institutes of Health's (NIH) Genetic Testing Registry - KAUZ-TV: Newschannel 6 Now | Wichita Falls, TX

Genomic Health's Oncotype DX® Becomes First Multi-Gene Test for Cancer Management To Be Included in National Institutes of Health's (NIH) Genetic Testing Registry

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Genomic Health, Inc.

Centralized database of gene-based tests enables easy access to information, improves transparency

REDWOOD CITY, Calif., May 14, 2014 /PRNewswire/ -- In response to continued advances in genomic technology and genetic medicine, the National Institutes of Health (NIH) has developed the Genetic Testing Registry (GTR), a free online resource, to provide physicians, researchers and patients with detailed and accurate information about genetic and genomic tests.  Comprehensive scientific and clinical information about the Oncotype DX® breast cancer test is now incorporated in the GTR database, representing Genomic Health's (NASDAQ: GHDX) leadership in applying genomic information to make cancer care smarter.

Genomic Health, Inc. logo.

"Over the last decade, in partnership with many collaborators, we have demonstrated that the rigorous validation of genomic information can transform cancer treatment," said Phil Febbo, M.D., chief medical officer, Genomic Health. "As new discoveries about the human genome continue to inspire medical innovations, we are proud to share the breadth of our clinical evidence to showcase how world-class science can be translated into a practice-changing test like Oncotype DX."

In addition to basic facts about the Oncotype DX breast cancer test, the GTR now offers detailed information about the test's development, validation and clinical utility to make this information easily accessible to physicians, researchers and patients.

"We are very pleased that Genomic Health has provided such extensive information about its Oncotype DX test in the GTR," said Wendy Rubinstein, M.D., Ph.D., director of the Genetic Testing Registry and senior scientist at the National Center for Biotechnology Information, a division of the National Library of Medicine at the National Institutes of Health. "With the growing interest in applications of genomics in cancer, it is particularly useful to have this level of detail available in a centralized database that also provides context-specific links to related peer-reviewed literature and practice guidelines."

The GTR features a versatile search interface that allows users to search by tests, conditions, genes, genetic mutations and laboratories. Information about the Oncotype DX breast cancer test can now be found at: http://www.ncbi.nlm.nih.gov/gtr/tests/509910/

Information about Genomic Health's tests for prostate, colon and non-invasive breast cancer will also be incorporated in the NIH's GTR later this year. To learn more about the GTR, visit http://www.ncbi.nlm.nih.gov/gtr/ or attend the NIH poster presentation at the American Society of Clinical Oncology® (ASCO®) Annual Meeting on Saturday, May 31, at McCormick Place in Chicago.

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from screening and surveillance, through diagnosis, treatment selection and monitoring.  Genomic Health's lead product, the Oncotype DX breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS).  In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease, and the Oncotype DX prostate cancer test, which predicts disease aggressiveness in men with low risk disease. As of March 31, 2014, more than 19,000 physicians in over 70 countries had ordered more than 440,000 Oncotype DX tests.  The company is based in Redwood City, California with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth. To learn more about OncotypeDX tests, visit: www.OncotypeDX.com, www.mybreastcancertreatment.org and www.myprostatecancertreatment.org.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's intent to continue its investment to capture significant opportunities in the international and genomic testing markets; the company's expectations regarding reporting study results; the attributes and focus of the company's product pipeline; the applicability of clinical study results to actual outcomes; the ability of any potential tests the company may develop to optimize cancer treatment; and the ability of the company to develop and commercialize additional tests in the future. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests and expand into new markets domestically and internationally; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts; the company's ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Form 10-Q for the period ended March  31, 2014. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

Logo - http://photos.prnewswire.com/prnh/20130425/SF01493LOGO

©2012 PR Newswire. All Rights Reserved.